证券代码：300981 证券简称：中红医疗 公告编号：2025-100 二、会议审议情况 1. 审议通过《关于聘任董事会秘书的议案》 鉴于张琳波先生申请辞去公司董事会秘书等职务，根据《公司法》《公司章 程》的有关规定，经公司董事会薪酬考核与提名委员会资格审核，董事会同意聘 任邓伟先生为公司第四届董事会的董事会秘书，上述任期自本次董事会审议通过 之日起至第四届董事会任期结束之日止。 该议案已经第四届董事会薪酬考核与提名委员会第六次会议全体成员审议 通过。 表决结果为：同意 9 票，反对 0 票，弃权 0 票。 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《关于董事会秘书辞职及聘任董事会秘书的公告》（公告编号：2025-101）。 中红普林医疗用品股份有限公司 第四届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十四 次会议于 2025 年 11 月 17 日以通讯方式召开，2025 年 11 月 12 日公 ...

Core Viewpoint - The company, Zhonghong Medical, is primarily engaged in the export of medical devices and consumables, benefiting from the depreciation of the RMB and focusing on innovation in medical products [2][4][3]. Group 1: Company Overview - Zhonghong Medical is a state-owned enterprise controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - The company was established on December 22, 2010, and went public on April 27, 2021. Its main business includes the research, production, and sales of high-quality nitrile gloves and PVC gloves [9]. - The revenue composition of the company is as follows: health protection products 89.48%, safety infusion products 6.22%, and innovative incubation products 4.30% [9]. Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38%. However, the net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [10]. - As of September 30, 2025, the company had a total market capitalization of 5.905 billion yuan, with a trading volume of 61.734 million yuan and a turnover rate of 1.14% [1]. Group 3: Market Position and Trends - The company’s overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. - Zhonghong Medical participated in the 12th Beijing Pet Expo, showcasing its veterinary infusion pumps, which received positive feedback for their safety and multifunctionality [2][3]. - The company aims to integrate digital technology into product development, focusing on high-quality and innovative medical consumables and equipment [3].

Core Insights - Zhonghong Medical's subsidiary, Kelong Medical, has successfully participated in bulk procurement projects across multiple provinces, enhancing its market presence in the medical consumables sector [1][2]. Group 1: Procurement Success - Kelong Medical has won bids for essential medical consumables such as vacuum blood collection tubes, nebulizers, intravenous catheters, and infusion sets in various provinces including Fujian, Beijing, and Yunnan [2]. - The selected products are recognized as clinical necessities, indicating stable market demand and a strong competitive edge [2][3]. Group 2: Product Strength and Market Performance - The products selected for procurement have established a solid reputation and customer base, demonstrating their market competitiveness through consistent performance [3]. - Kelong Medical's core products have maintained robust market performance, supported by precise understanding of clinical needs and ongoing product optimization [3]. Group 3: Market Expansion and Long-term Development - The bulk procurement initiative is a significant opportunity for Kelong Medical, promising stable market orders and expanded market space [4]. - The procurement rules ensure that medical institutions prioritize Kelong Medical's selected products, which will enhance market share and brand influence [4]. - This breakthrough in procurement is a critical advancement for Zhonghong Medical in the medical consumables sector, allowing for better alignment with industry trends and improved supply chain efficiency [4]. Group 4: Future Growth Prospects - The successful procurement is a testament to Kelong Medical's long-term focus on product quality and market strategy [5]. - With the anticipated signing and execution of procurement contracts, Kelong Medical is expected to further increase market coverage and share, driving sustainable growth for Zhonghong Medical [5]. - This achievement opens new development avenues and positions the company to lead in the high-quality development wave of the medical consumables industry [5].

Core Viewpoint - 中红医疗 is experiencing growth in its stock price and market activity, driven by its focus on medical devices, pet economy, and international sales, particularly benefiting from the depreciation of the RMB [1][4]. Group 1: Company Overview - 中红医疗 primarily engages in ODM production for overseas medical device brands, focusing on self-designed and self-manufactured products [2]. - The company was established on December 22, 2010, and went public on April 27, 2021, specializing in high-quality disposable protective gloves and medical supplies [9]. - As of September 30, 2025, 中红医疗 reported a revenue of 1.864 billion yuan, a year-on-year increase of 1.38%, but a net profit loss of 7.21 million yuan, a decrease of 114.13% year-on-year [10]. Group 2: Product and Market Focus - 中红医疗 showcased its products at the 12th Beijing Pet Expo, highlighting its veterinary infusion pumps, which are designed for safety and multifunctionality [2]. - The company emphasizes innovation and digital technology integration in developing high-performance medical products to meet diverse market needs [3]. - In 2024, overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Financial and Shareholder Information - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan in the last three years [11]. - As of September 30, 2025, the number of shareholders increased to 22,400, with an average of 17,531 shares held per person, a decrease of 10.11% from the previous period [10].

Group 1 - Jinguang Electric won a bid for a State Grid procurement project with a total amount of 21.7976 million yuan, accounting for approximately 2.93% of the company's expected revenue for 2024 [1] - Shen Gong Co. plans to reduce its shareholding by up to 2%, equating to 340.61 million shares [2] - Guomai Culture received a government subsidy of 3.78 million yuan, representing 24.90% of its audited net profit for 2024 [2] Group 2 - Guomai Culture focuses on the development and provision of digital content operation platforms [3] - Shentong Technology's two directors plan to collectively reduce their shareholding by no more than 0.0473% [4] - Ruihua Tai intends to reduce its shareholding by up to 1%, amounting to 1.8 million shares [5] Group 3 - Guoji Automobile's wholly-owned subsidiary won a total contract project worth 809 million yuan [7] - Changcheng Technology's stock is expected to remain suspended due to potential changes in control [9] - Huabei Pharmaceutical's subsidiary received approval for a chemical raw material drug listing application [11] Group 4 - Fuyao Glass has changed its legal representative to Cao Hui [13] - Huaxi Biological plans to reduce its shareholding by up to 2%, totaling 9.6336 million shares [14] - Hopu Co. signed a procurement contract for a storage system worth 500 million yuan [15] Group 5 - ST Songfa's subsidiary plans to invest 458 million yuan in a mooring dock project [18] - Zhonghong Medical's subsidiary is expected to be selected for several centralized procurement projects [19] - Huakai Yibai's vice chairman plans to increase his shareholding by no less than 30 million yuan [20] Group 6 - Haichuang Pharmaceutical completed the first participant enrollment for a clinical trial of a drug for metabolic-associated fatty liver disease [21] - Dongfang Biological's subsidiary obtained medical device product registration certificates for multiple products [22] - Lepu Medical's rechargeable implantable deep brain stimulation system received NMPA registration approval [23] Group 7 - Changyuan Power's power generation in October decreased by 32.25% year-on-year [24] - Jinshi Yaya's diclofenac sodium sustained-release tablets passed the consistency evaluation for generic drugs [26] - Yutong Bus sold 3,040 buses in October, a decrease of 5.62% year-on-year [27] Group 8 - Far East Co. signed contracts worth 1.062 billion yuan in October [28] - Tianya Pharmaceutical's subsidiary passed the consistency evaluation for a drug [29] - Yuheng Pharmaceutical plans to resolve a debt dispute through a share transfer agreement [30] Group 9 - Hailanxin's subsidiary won a bid for a marine observation network project worth 1.097 billion yuan [31] - Huasheng Lithium plans to reduce its shareholding by up to 0.37% [33] - Maike Biological obtained product registration certificates for five new in vitro diagnostic products [34] Group 10 - Huayuan New Materials signed a strategic cooperation agreement with Taiblue New Energy [37] - Greebo's actual controller and some directors plan to collectively increase their shareholding by no less than 11.5 million yuan [39] - Yian Technology received a government subsidy of 1.1643 million yuan [41] Group 11 - Kangtai Biological's quadrivalent influenza virus vaccine has commenced Phase I clinical trials [43] - Spring Airlines received a commitment letter for a stock repurchase loan of up to 450 million yuan [45] - Foton Motor sold 8,006 new energy vehicles in October, a year-on-year increase of 98.83% [46] Group 12 - Greebo plans to transfer 100% equity of its subsidiary for 280 million yuan [48] - Siwei Liekong's director is under investigation [49] - Dingyang Technology launched a new generation of multi-channel microwave signal generator products [50] Group 13 - Jiangling Motors reported a year-on-year increase of 8.06% in vehicle sales for October [51] - Shengyi Technology plans to reduce its shareholding by up to 1.03% [52] - Dongshan Precision completed the acquisition of 100% equity of France's GMD Group for approximately 814 million yuan [53] Group 14 - Tianyang Technology plans to acquire 7.5% of Baoland's shares for 155 million yuan [54] - Alter plans to establish a joint venture company with a total investment of 672 million yuan [54] - Changchun High-tech's clinical trial application for a drug was approved [55] Group 15 - Beibu Gulf Port's cargo throughput in October increased by 22.73% year-on-year [56] - ST Zhangjiajie was ruled by the court to undergo reorganization [57] - Teda Co.'s subsidiary was selected as a supplier for an energy project in Indonesia [58]

Core Viewpoint - The announcement by Zhonghong Medical on November 4 indicates that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd. (referred to as "Kelong Medical"), has participated in bidding for centralized procurement projects in multiple cities and provinces, with potential selection of several products [1] Group 1: Procurement Projects - Kelong Medical is involved in bidding for centralized procurement projects in Putian City, Fuzhou City, Beijing, and Qujing City [1] - The products targeted for selection include disposable vacuum blood collection tubes, disposable nebulizers, and disposable intravenous indwelling needles [1] Group 2: Market Impact - If selected, the medical institutions in the procurement regions will prioritize the use of Kelong Medical's products during the procurement cycle, ensuring the completion of the agreed procurement volume [1] - The subsequent signing of sales contracts and implementation will help expand the market sales of the selected products, increase market share, and enhance brand influence, positively impacting the company's long-term development [1]

证券代码：300981 证券简称：中红医疗 公告编号：2025-099 中红普林医疗用品股份有限公司 关于子公司参与集中带量采购项目拟中选的公告 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期分别参加了福建省莆田 市"Y 接头、真空采血管全省性联盟集中带量采购项目"、福建省福州市"一次 性使用温度传感器、雾化器全省性联盟集中带量采购项目"、北京市"静脉留置 针类及输液器类医用耗材集中带量采购项目"、云南省曲靖市"第七批医用耗材 （全省联盟）扩围带量采购项目"的投标工作。分别根据福建省莆田市"Y 接头、 真空采血管全省性联盟集中带量采购公告（第 7 号）"、福建省福州市"雾化器 全省性联盟集中带量采购公告（第 9 号）"、北京市"静脉留置针类、输液器类 医用耗材集中带量采购中选结果及委托配送企业的通知"、云南省曲靖市"第七 批医用耗材（全省联盟）扩围带量采购中选公告"显示，科伦医械部分产品拟中 选上述集中带量采购项目。现将相关情况公告如下： 品种分类 型号规格 中标产品及 注册证号 注册分类 适用范围 拟中选价 格及数量 拟供应 地区 一次 ...

Core Insights - The article reports on recent shareholding changes among executives at Zhonghong Medical, highlighting a significant increase in shares by General Manager Yang Hao despite a decline in the company's stock price [1][2]. Executive Shareholding Changes - On October 30, 2025, Yang Hao purchased 25,000 shares, representing 0.0058% of the total share capital, at an average price of 12.93 yuan per share, while the stock price fell by 2.07% to close at 12.78 yuan [1]. - In the past six months, Yang Hao has made several transactions, including a purchase of 5,000 shares on September 25 at 13.31 yuan and another purchase of 20,000 shares on September 22 at 13.55 yuan [1]. Current Executive Shareholding Status - The current shareholding status of executives shows that: - Chairman and legal representative Sang Shujun holds 47.77 million shares. - Yang Hao, the General Manager, now holds 50,000 shares after the recent purchase [2]. - Other executives, including Vice General Managers and non-independent directors, have not reported any shareholdings or recent changes [2]. Financing and Margin Trading Data - Recent financing data indicates a net inflow of 4.4264 million yuan in the last five days, with an increase in financing balance, while there was no net inflow in margin trading [2]. Institutional Ratings - There have been no institutional ratings for the stock in the last 90 days [3].

Core Points - The company Zhonghong Medical announced the completion of its share buyback plan as of the announcement date [1] - The total shares purchased by the company's general manager, Ms. Yang Hao, amounted to 50,000 shares, representing 0.0117% of the company's shares excluding those in the repurchase account [1] - The total amount spent on the share purchase was RMB 661,264.48, excluding transaction fees [1]

Core Viewpoint - Zhonghong Medical (300981.SZ) has completed its share buyback plan, reaching the lower limit of the intended increase in shareholding [1] Summary by Categories Shareholding Increase - Ms. Yang Hao has cumulatively increased her shareholding by 50,000 shares through the Shenzhen Stock Exchange's centralized bidding system, which accounts for 0.0117% of the company's shares excluding those in the repurchase account [1] - The total amount spent on the increased shares is RMB 661,264.48 (excluding transaction fees) [1]